SUTRO BIOPHARMA INC.

Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer

09 7 2024 05:00:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

13 5 2024 13:30:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

30 4 2024 05:00:01 提供 Nasdaq GlobeNewswire

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

02 4 2024 03:18:56 提供 Nasdaq GlobeNewswire

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

25 3 2024 13:30:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma to Participate in Upcoming Investor Conferences

06 2 2024 13:05:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

04 1 2024 13:05:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

14 12 2023 13:05:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

11 12 2023 13:05:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit

04 12 2023 13:05:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

21 11 2023 13:05:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

13 11 2023 13:30:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023

22 10 2023 01:25:00 提供 Nasdaq GlobeNewswire

Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference

16 10 2023 13:05:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer

19 9 2023 05:00:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma to Participate in Upcoming Investor Conferences

30 8 2023 05:00:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

10 8 2023 13:30:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration

26 6 2023 05:00:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1

03 6 2023 13:00:00 提供 Nasdaq GlobeNewswire

Sutro Biopharma to Participate in the Jefferies Healthcare Conference

31 5 2023 05:00:00 提供 Nasdaq GlobeNewswire